Stock comparison
Align Technology
Genmab A/S
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
ALGN
Align Technology
Market cap
$11.72B
Sector
Healthcare
GMAB
Genmab A/S
Market cap
$16.5B
Sector
Healthcare
Overall winner
Genmab A/S GMAB
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | ALGN | GMAB | Winner |
|---|---|---|---|
| Warren Buffett | 56C | 65C | GMAB |
| Benjamin Graham | 66B | 64C | ALGN |
| Philip Fisher | 40D | 48D | GMAB |
| Peter Lynch | 18F | 25F | GMAB |
| Joel Greenblatt | 36D | 76B | GMAB |
| Charlie Munger | 42D | 68C | GMAB |
| Terry Smith | 44D | 71C | GMAB |
Side-by-side metrics
| Metric | ALGN | GMAB |
|---|---|---|
| Market cap | $11.72B | $16.5B |
| P/E (TTM) | 26.1x | 6.2x |
| EV/EBIT | 16.7x | 12.0x |
| ROIC (TTM) | 9.72% | 43.78% |
| Gross margin | 67.68% | 93.88% |
| Net margin | 10.5% | 18.23% |
| Revenue CAGR 5y | 0.52% | -18.45% |
| EPS CAGR 5y | -12.78% | -23.48% |
| Debt / Equity | 0.0x | 0.1x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
ALGN leads on
- Revenue CAGR 5y0.52%vs -18.45%+103%
- Debt / Equity0.0xvs 0.1x+73%
- EPS CAGR 5y-12.78%vs -23.48%+46%
GMAB leads on
- ROIC (TTM)43.78%vs 9.72%+78%
- P/E (TTM)6.2xvs 26.1x+76%
- Net margin18.23%vs 10.5%+42%
- Market cap$16.5Bvs $11.72B+29%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.